Gregory Alan Korbel is VP at Aprea Therapeutics, Inc. (APRE). They have made 5 open-market trades across 1 company since 2019, most recently 2022-07-28.
CIK 0001789032
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $8K since 2019, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| APRE | 45,762 | $27K |
Shares reported on the most recent Form 4, priced at the 2022-08-01 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| APRE | SELL | 2021-12-01 | 2021-12-03 | $3.96 | $109K | -5.0% | -12.7% | -53.9% |
| APRE | SELL | 2021-11-01 | 2021-11-03 | $5.00 | $138K | -7.3% | -29.0% | -58.1% |
| APRE | SELL | 2021-10-01 | 2021-10-05 | $4.89 | $134K | +2.4% | +2.0% | -37.1% |
| APRE | SELL | 2021-09-20 | 2021-09-22 | $4.97 | $164K | +18.1% | +6.0% | -25.4% |
| APRE | BUY | 2019-10-07 | 2019-10-07 | $15.00 | $8K | +1.4% | +23.8% | +111.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.